Cargando…
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients. The integration of the next generation of proteasome inhibitors and antibody therapeu...
Autores principales: | Nishihori, Taiga, Song, Jinming, Shain, Kenneth H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819726/ https://www.ncbi.nlm.nih.gov/pubmed/26898557 http://dx.doi.org/10.1007/s11899-016-0308-3 |
Ejemplares similares
-
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022) -
The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018) -
MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021) -
Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019) -
Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)